You are here

Daiichi Sankyo

Daiichi Sankyo to cut 69 opioid sales jobs

Daiichi Sankyo to cut 69 opioid sales jobs

Beckers Hospital Review

Flag link:

Daiichi Sankyo scores landmark FDA OK for rare tumor drug — albeit with restrictions

Daiichi Sankyo scores landmark FDA OK for rare tumor drug — albeit with restrictions

Endpoints

tenosynovial giant cell tumors

Flag link:

FDA declines to approve Daiichi Sankyo's blood cancer treatment

FDA declines to approve Daiichi Sankyo's blood cancer treatment

Reuters

acute myeloid leukemia

Flag link:

5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit

5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit

Motley Fool

Vertex Pharmaceuticals

tezacaftor/ivacaftor

trastuzumab deruxtecan

Flag link:

Daiichi Sankyo Denies Report That It's Selling Over-the-Counter Drug Unit

Daiichi Sankyo Denies Report That It's Selling Over-the-Counter Drug Unit

BioSpace

Flag link:

Daiichi Sankyo in talks over OTC unit sale – reports

Daiichi Sankyo in talks over OTC unit sale – reports

Pharmaforum

Flag link:

Daiichi Sankyo comes up way short of promised avian flu vaccine production

Daiichi Sankyo comes up way short of promised avian flu vaccine production

Fierce Pharma

Flag link:

Daiichi Sankyo Takes Two Products to FDA Advisory Panel; Gets One Yes, One No

Daiichi Sankyo Takes Two Products to FDA Advisory Panel; Gets One Yes, One No

BioSpace

acute myeloid leukemia

Flag link:

FDA questions credibility of Daiichi data ahead of AdComm

FDA questions credibility of Daiichi data ahead of AdComm

Fierce Biotech

acute myeloid leukemia

Flag link:

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Yahoo/Benzinga

The Medicines Company

Flag link:

AstraZeneca's share dilution gamble on Daiichi drug pays off

AstraZeneca's share dilution gamble on Daiichi drug pays off

Biopharma Dive

trastuzumab deruxtecan

metastatic breast cancer

Flag link:

AZ and Daiichi to file new breast cancer drug after trial success

AZ and Daiichi to file new breast cancer drug after trial success

Pharmaforum

trastuzumab deruxtecan

antibody-drug conjugate

Flag link:

Daiichi picks immuno-oncology bispecific, triggering payout to Zymeworks

Daiichi picks immuno-oncology bispecific, triggering payout to Zymeworks

Fierce Biotech

immuno-oncology

bispecific antibodies

Flag link:

AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal

AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal

Yahoo/Reuters

trastuzumab deruxtecan

Flag link:

Doubling down on R&D, Daiichi makes executive changes across its U.S. research unit

Doubling down on R&D, Daiichi makes executive changes across its U.S. research unit

Fierce Biotech

Flag link:

Daiichi gets speedy FDA review for rare cancer drug

Daiichi gets speedy FDA review for rare cancer drug

Pharmaforum

priority review

Flag link:

Daiichi Sankyo takes option on diabetes stem cell start-up

Daiichi Sankyo takes option on diabetes stem cell start-up

Pharmaforum

Tokyo Institute of Technology

type 1 diabetes

OiDE BetaRevive

Flag link:

Daiichi Sankyo lines up a $900M deal for rights to a cholesterol drug looking to disrupt a blockbuster market

Daiichi Sankyo lines up a $900M deal for rights to a cholesterol drug looking to disrupt a blockbuster market

Endpoints

Esperion Therapeutics

Flag link:

Daiichi Sankyo signs clinical trial collaboration deal with Merck and Pfizer

Daiichi Sankyo signs clinical trial collaboration deal with Merck and Pfizer

Pharmaceutical Business Review

clinical trials

Flag link:

Daiichi Sankyo launches phase 1 trial of DS-1205 in EGFR-mutated NSCLC

Daiichi Sankyo launches phase 1 trial of DS-1205 in EGFR-mutated NSCLC

Pharmaceutical Business Review

non-small cell lung cancer

Flag link:

Pages